
Dec 17 (Reuters) - PFIZER:
PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL & STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, & OVERALL SURVIVAL
PFIZER: PATHOLOGIC COMPLETE RESPONSE RATE FOR NEOADJUVANT PADCEV PLUS PEMBROLIZUMAB VERSUS NEOADJUVANT CHEMOTHERAPY WAS MET
PFIZER: PADCEV PLUS KEYTRUDA SIGNIFICANTLY IMPROVES SURVIVAL FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITY
PFIZER: SAFETY PROFILE FOR PADCEV PLUS PEMBROLIZUMAB WAS CONSISTENT WITH KNOWN PROFILE OF TREATMENT REGIMEN